Department of Pharmacy, First hospital of shanxi medical university, No. 85 Jiefang South Road, Taiyuan City, 030001, Shanxi Province, China.
Department of Colorectal and anal surgery, Shanxi provincial people's hospital, Taiyuan City, 030001, Shanxi Province, China.
BMC Pharmacol Toxicol. 2024 Sep 3;25(1):61. doi: 10.1186/s40360-024-00769-z.
To analyse the clinical efficacy and adverse drug reactions (ADRs) of iron preparations.
A total of 374 patients with iron deficiency anaemia admitted to our hospital between 1 January and 31 December 2020 were included in this study. They were divided into 2 groups based on their medication regimens: Group A (n = 187) took oral ferrous succinate tablets, and Group B (n = 187) received intravenous iron sucrose. The remission of major symptoms, laboratory test results, ADRs and other related data were collected after 4 weeks of treatment.
Compared with the pre-treatment baseline, haemoglobin (Hb), serum iron (SI), serum ferritin (SF) and the mean corpuscular volume (MCV) increased in both groups at 4 weeks of treatment (P < 0.05). After treatment, Group A had lower levels of Hb (108.41 ± 8.39 vs. 122.31 ± 6.04 g/L, t = 6.293, P < 0.001), SI (9.72 ± 4.24 vs. 15.62 ± 5.41 µmol/L, t = 5.482, P < 0.001) and SF (27.1 ± 10.82 vs. 39.82 ± 10.44 ug/L, t = 6.793, P < 0.001) compared with Group B. In contrast, there was no significant difference in the post-treatment level of MCV (P > 0.05). The overall response rate significantly differed between the 2 groups (78.61% vs. 90.91%, χ = 10.949, P < 0.001). The incidence of ADRs of both groups were similar, and the difference was not statistically significant (χ = 0.035, P = 0.851).
Iron sucrose demonstrates favourable efficacy and safety in treating iron deficiency anaemia.
分析铁制剂的临床疗效和药物不良反应（ADR）。
选取 2020 年 1 月 1 日至 12 月 31 日我院收治的 374 例缺铁性贫血患者，根据用药方案分为两组，A 组（n=187）口服琥珀酸亚铁片，B 组（n=187）静脉滴注蔗糖铁。两组均治疗 4 周后，收集主要症状缓解情况、实验室检查结果、ADR 等相关数据。
与治疗前基线相比，两组患者治疗 4 周后血红蛋白（Hb）、血清铁（SI）、血清铁蛋白（SF）、平均红细胞体积（MCV）均升高（P<0.05）。治疗后 A 组 Hb（108.41±8.39 vs. 122.31±6.04 g/L，t=6.293，P<0.001）、SI（9.72±4.24 vs. 15.62±5.41 μmol/L，t=5.482，P<0.001）、SF（27.1±10.82 vs. 39.82±10.44 ug/L，t=6.793，P<0.001）低于 B 组，差异有统计学意义（P<0.05）；而两组 MCV 治疗后比较差异无统计学意义（P>0.05）。两组总体有效率比较差异有统计学意义（78.61% vs. 90.91%，χ²=10.949，P<0.001）。两组 ADR 发生率比较差异无统计学意义（χ²=0.035，P=0.851）。
蔗糖铁治疗缺铁性贫血疗效确切，安全性好。
